The Anti-Parkinsonian A2A Receptor Antagonist Istradefylline (KW-6002) Attenuates Behavioral Abnormalities, Neuroinflammation, and Neurodegeneration in Cerebral Ischemia: An Adenosinergic Signaling Link Between Stroke and Parkinson’s Disease
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26125680 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Michael G Zaki und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Neuroscience Research Cluster, College of Medicine, University of Saskatchewan, 107 Wiggins Road, Saskatoon, SK S7N 5E5, Canad…. Hauptthemen laut MEDLINE: Purines, Adenosine A2 Receptor Antagonists, Parkinson Disease, Brain Ischemia. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Heart and Stroke Foundation of Canada, Saskatchewan Health Research Foundation Collaborative Innovation and Development Grant, Natural Sciences and Engineering Research Council of Canada Discovery Grant.
Themen: Schlaganfall
Abstract (Originalsprache)
Stroke, the third leading cause of death worldwide, is a major cause of functional disability. Cerebral ischemia causes a rapid elevation of adenosine, the main neuromodulator in the brain. The inhibition of adenosine A2A receptors (A2ARs) has been introduced as a potential target in neurodegenerative disorders involving extracellular adenosine elevation. Istradefylline, a selective A2AR antagonist, has been approved for Parkinson’s disease (PD) adjunctive therapy and showed neuroprotective effects in PD and Alzheimer’s disease. However, the role of A2ARs in post-stroke neuronal damage and behavioral deficits remains unclear. We recently showed that A2AR antagonism prevented the adenosine-induced post-hypoxia synaptic potentiation of glutamatergic neurotransmission following the hypoxia/reperfusion of hippocampal slices. Here, we investigated the potential neuroprotective effects of istradefylline in male Sprague-Dawley rats subjected to pial vessel disruption (PVD) used to model a small-vessel stroke. Rats were treated with either a vehicle control or istradefylline (3 mg/kg i.p.) following PVD surgery for three days. Istradefylline administration prevented anxiety and depressive-like behaviors caused by PVD stroke. In addition, istradefylline significantly attenuated ischemia-induced cognitive impairment and motor deficits. Moreover, istradefylline markedly reduced hippocampal neurodegeneration, as well as GFAP/Iba-1, TNF-α, nNOS, and iNOS levels after PVD, but prevented the downregulation of anti-inflammatory markers TGF-β1 and IL-4. Together, these results suggest a molecular link between stroke and PD and that the anti-PD drug istradefylline displays translational potential for drug repurposing as a neuroprotective agent for cerebral ischemic damage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Neuroscience Research Cluster, College of Medicine, University of Saskatchewan, 107 Wiggins Road, Saskatoon, SK S7N 5E5, Canada.
- Department of Anatomy, Physiology and Pharmacology, University of Saskatchewan, 107 Wiggins Road, Saskatoon, SK S7N 5E5, Canada.
ORCID-Profile: Michael G Zaki, Changiz Taghibiglou, Francisco S Cayabyab
Förderung
- Heart and Stroke Foundation of Canada
- Saskatchewan Health Research Foundation Collaborative Innovation and Development Grant
- Natural Sciences and Engineering Research Council of Canada Discovery Grant
- Natural Sciences and Engineering Research Council of Canada
- University of Saskatchewan
Zitieren
APA
Zaki, M. G., Jakova, E., Pordeli, M., Setork, E., Taghibiglou, C., & Cayabyab, F. S. (2025). The Anti-Parkinsonian A2A Receptor Antagonist Istradefylline (KW-6002) Attenuates Behavioral Abnormalities, Neuroinflammation, and Neurodegeneration in Cerebral Ischemia: An Adenosinergic Signaling Link Between Stroke and Parkinson’s Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26125680
Vancouver
Zaki MG, Jakova E, Pordeli M, Setork E, Taghibiglou C, Cayabyab FS. The Anti-Parkinsonian A2A Receptor Antagonist Istradefylline (KW-6002) Attenuates Behavioral Abnormalities, Neuroinflammation, and Neurodegeneration in Cerebral Ischemia: An Adenosinergic Signaling Link Between Stroke and Parkinson’s Disease. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26125680
BibTeX
@article{Zaki2025,
author = {Zaki, Michael G and Jakova, Elisabet and Pordeli, Mahboubeh and Setork, Elina and Taghibiglou, Changiz and Cayabyab, Francisco S},
title = {The Anti-Parkinsonian A2A Receptor Antagonist Istradefylline (KW-6002) Attenuates Behavioral Abnormalities, Neuroinflammation, and Neurodegeneration in Cerebral Ischemia: An Adenosinergic Signaling Link Between Stroke and Parkinson’s Disease},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26125680}
}
EUVIMED